Confirmation of Board Changes, NetScientific PLC, 2020-05-01

RNS Number : 6765L
NetScientific PLC
01 May 2020



NetScientific plc

(“NetScientific” or the “Company”)


Confirmation of Board Changes



London, UK – 1 May 2020 – NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, confirms the anticipated management changes announced on 31 March 2020.


Ian Postlethwaite resigned from the Board and stepped down as CEO/CFO and Company Secretary on 30 April 2020.


At the same time, Dr. Ilian Iliev, previously a Non-Executive Director, was appointed part time Executive Director and interim CEO. Ilian, who also joined the Board of NSCI portfolio company Glycotest, Inc., will continue in his role as MD of EMV Capital, also in a part time capacity.


Stephen Crowe, Group Financial Controller since 2018, took over as interim CFO and Company Secretary.


Finally, John Clarkson joined the Board of ProAxsis UK limited.


John Clarkson, Chairman of NetScientific, said: “I look forward to working with Ilian and Stephen in delivering the requisite proactive management and implementing strategic improvements.”


#  #  #


For more information, please contact:



  Ilian Iliev, CEO

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666

MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977



About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. 


For more information, please visit the website at

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.